Related Experiment Videos
Immunosuppressive therapy in lupus nephritis
D D'Cruz1, M J Cuadrado, F Mujic
1Lupus Arthritis Research Unit, Rayne Institute, London, U.K.
Clinical and Experimental Rheumatology
|May 1, 1997
Summary
Immunosuppressive therapy, including cyclophosphamide and azathioprine, helped preserve kidney function in lupus nephritis patients. This treatment showed a notable reduction in ovarian failure compared to other regimens.
Area of Science:
- Nephrology
- Immunology
- Rheumatology
Background:
- Lupus nephritis is a severe complication of systemic lupus erythematosus.
- Immunosuppressive therapy is the cornerstone of treatment for lupus nephritis.
- Evaluating treatment outcomes and side effects is crucial for optimizing patient care.
Purpose of the Study:
- To assess the efficacy and safety of immunosuppressive regimens in lupus nephritis patients.
- To determine the impact of therapy on renal function and laboratory parameters.
- To compare the incidence of side effects, particularly ovarian failure, with existing literature.
Main Methods:
- A retrospective study of 39 biopsy-proven lupus nephritis patients (1988-1993).
- Treatment involved intravenous cyclophosphamide pulses followed by azathioprine or oral cyclophosphamide, with oral prednisolone.
- Renal insufficiency (doubled creatinine or end-stage renal failure) was the primary outcome measure.
Main Results:
- Significant improvements observed in major laboratory parameters.
- Renal function remained stable in 67% of patients; 33% experienced deterioration.
- Adverse effects included infections, leucopenia, rash, ovarian failure, and fatal septicaemia, varying by drug regimen.
Conclusions:
- Weekly low-dose intravenous pulse cyclophosphamide followed by azathioprine is effective in preserving renal function in diffuse proliferative lupus nephritis.
- This regimen demonstrated a striking reduction in ovarian failure incidence.
- The findings support this therapeutic approach for managing lupus nephritis.